Missed the webinar? Here are Investing.com’s top 10 stock picks for 2026
Inmune Bio Inc. (NASDAQ:INMB) disclosed on Wednesday that it has entered into new employment agreements with its President and Chief Executive Officer David J. Moss, Chief Financial Officer Cory Ellspermann, and Chief Scientific Officer Mark Lowdell, effective November 1, 2025. The information is based on a press release statement contained in a recent SEC filing.
Under the agreement, Mr. Moss will receive a base salary of $500,000 per year and is eligible for an annual discretionary bonus targeted at 50% of his base salary, prorated for the days employed during the year. He has also been granted an option to purchase 800,000 shares of Inmune Bio common stock under the company’s 2021 Stock Incentive Plan. Any unvested portion of this option will vest immediately upon a Change of Control, provided Mr. Moss remains in service through the closing date. In the event of an involuntary termination, Mr. Moss would be entitled to 18 months of base salary, a prorated annual bonus, and COBRA premiums or equivalent payments for up to 18 months, subject to the execution and non-revocation of a separation agreement and release of claims.
Mr. Ellspermann’s agreement includes a base salary of $275,000 per year and eligibility for an annual discretionary bonus targeted at 40% of base salary. He was granted an option to purchase 300,000 shares of company stock, with similar vesting provisions to those of Mr. Moss. In case of involuntary termination, Mr. Ellspermann would receive 18 months of base salary, a prorated annual bonus, and COBRA premiums or equivalent payments for up to 18 months, subject to the same conditions as above.
Mr. Lowdell, Chief Scientific Officer, entered into an agreement with Inmune Bio International Limited, a wholly owned subsidiary. He will receive an annual base salary of £300,000, payable monthly, and is eligible for a discretionary bonus of up to 20% of base salary, subject to performance criteria. The agreement allows either party to terminate employment with three months’ notice. If terminated by the subsidiary other than for cause, death, or permanent disability, Mr. Lowdell is entitled to 18 months of base salary as severance, subject to statutory deductions and a release of claims.
All agreements include confidentiality and intellectual property provisions.
In other recent news, INmune Bio Inc reported its third-quarter earnings for 2025, surpassing analysts’ expectations. The company posted an earnings per share (EPS) of -0.24, which was better than the forecasted EPS of -0.33. This indicates a reduced loss compared to previous periods, signaling some financial improvement. Despite this earnings beat, the company’s stock experienced a decline of 1.65% in aftermarket trading, closing at $1.79. This drop suggests that investors remain cautious about the company’s ongoing financial challenges. No major mergers or acquisitions were reported in this period. Additionally, there were no analyst upgrades or downgrades provided in the recent updates. These developments highlight the current financial landscape for INmune Bio as it continues to navigate its business operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.